Antithrombotic therapy in children

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 344S-370S

  Monagle, P ^a   Michelson, A D ^a   Bovill, E ^a   Andrew, M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CARBAMAZEPINE; CEFACLOR; CLOPIDOGREL; CLOXACILLIN; COTRIMOXAZOLE; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PHYTOMENADIONE; PREDNISONE; PROTAMINE SULFATE; RANITIDINE; REVIPARIN; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TIME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DISPOSITION; DRUG MECHANISM; DRUG MONITORING; HEART CATHETERIZATION; HEART VALVE PROSTHESIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; OSTEOPOROSIS; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; UMBILICAL ARTERY CATHETERIZATION;

EID: 0035121602     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.344S     Document Type: Conference Paper

References (350)

1. Oral anticoagulant therapy in pediatric patients: A prospective study
2. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor
3. Antithrombotic therapy in children
4. Supranormalizing antithrombin levels is safe in children with acute lymphoblastic leukemia treated with L-asparaginase: Results of the PARKAA study
5. A prospective cohort determining the incidence of thrombotic events in children with acute lymphoblastic leukemia treated with L-asparaginase: Results of the PARKAA study
6. Comparison of venography with ultrasound for the detection of venous thrombosis in die upper body in children: Results of the PARKAA study
7. Development of the human coagulation system in the full-term infant
8. Development of the hemostatic system in the neonate and young infant
9. Development of the human coagulation system in the healthy premature infant
10. Thrombin inhibition is impaired in plasma of sick neonates
11. Evolution of blood coagulation activators and inhibitors in the healthy human fetus
12. Heparin and low molecular weight heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
13. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
14. Anticoagulant effects of heparin in neonatal plasma
15. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin
16. Thrombin regulation in children differs from adults in the absence and presence of heparin
17. Heparin
18. Heparin therapy in pediatric patients: A prospective cohort study
19. The weight-based heparin dosing nomogram compared with a "standard care" nomogram
20. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
21. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
22. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis
23. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs
24. Heparin clearance in the newborn
25. Heparin is cleared faster in children with congenital heart disease than adults
26. Heparin kinetics in venous thrombosis and pulmonary embolism
27. Increased heparin clearance in experimental pulmonary embolism
28. A standard heparin nomogram for the management of heparin therapy
29. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis
30. Heparin induced osteoporosis: An appraisal
31. Heparin induced osteoporosis
32. Heparin therapy and bone fractures
33. Heparin-induced thrombocytopenia in children
34. Heparin-induced thrombocytopenia in the newborn
35. Cardiopulmonary bypass in patients with heparin induced thrombocytopenia using Organon 10172
36. Heparin induced thrombocytopenia in a child
37. Heparin as a cause of thrombus progression: Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts
38. Heparin-induced thrombocytopenia in children
39. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
40. Heparin induced thrombocytopenia in a young child managed with Orgaran for cardiopulmonary bypass surgery
41. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
42. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE)
43. Treatment of homozygous protein C deficiency in two children with low molecular weight heparin (LMWH) therapy
44. The comparison of the pharmacokinetics of a low molecular heparin in the newborn and adult pig
45. Low molecular weight heparin
46. Partial reversal of low molecular weight heparin (PK 10169) anti Xa activity by protamine sulfate: In vitro and in vivo study during cardiac surgery with extracorporeal circulation
47. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man
48. Neutralization of enoxaparine induced bleeding by protamine sulfate
49. Does low molecular weight heparin cause bleeding?
50. Determination of trough anti-factor Xa levels in pediatric patients on low molecular weight heparin (LMWH)
51. The use of low molecular weight heparin in pediatric patients: A prospective cohort study
52. Report of scientific and standardization subcommittee on neonatal hemostasis
53. Normal hemostasis in fetus and newborn: Coagulation
54. Vitamin K1 metabolism and the production of des-carboxy prothrombin and protein C in the term and premature neonate
55. Maturation of the hemostatic system during childhood
56. Coumarin suppresses thrombin regulation to a greater extent in children compared to adults
57. Report of scientific and standardization subcommittee on neonatal hemostasis diagnosis and treatment of neonatal thrombosis
58. Enhanced thrombin regulation during warfarin therapy in children compared to adults
59. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement
60. Analysis of warfarin therapy in pediatric patients: A prospective cohort study
61. Anticoagulation therapy in children with mechanical prosthetic cardiac valves
62. Clinical experience with an oral anticoagulant in children
63. Antithrombotic therapy in children and adolescents
64. Anticoagulation with sodium warfarin in children: Effect of a loading regimen
65. Survey of oral anticoagulant treatment in children
66. Use of antiplatelet agents in pediatric hypercoagulable states
67. Oral anticoagulation in paediatric patients: Dose requirements and complications
68. Oral anticoagulant drugs: Review article
69. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE
70. Coagulation changes in the neonatal period and in early infancy
71. 1 in mothers and their newborn babies
72. 2 (menaquinone) status in newborns during the first week of life
73. 1) in human milk, cow's milk and infant formula foods determined by high-performance liquid chromatography
74. 1 supplements given to the mother
75. The hemostatic system in the infant
76. Warfarin absorption in a patient with short-bowel syndrome
77. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy
78. The long-term risk of warfarin sodium therapy and the incidence of thromboembolism in children after prosthetic cardiac valves
79. Prosthetic heart valve replacement in children
80. Valve prostheses in children: A reassessment of anticoagulation
81. Anticoagulant therapy in children with prosthetic valves
82. The choice of anticoagulation in pediatric patients with the St. Jude Medical valve prostheses
83. Thromboembolic and other events following valve replacement in a pediatric population treated with antiplatelet agents
84. Valve replacement in children less than 5 years of age
85. Ten-year follow-up after valve replacement with the St. Jude Medical prosthesis in children
86. Tracheobronchial calcification: An observation in three children after mitral valve replacement and warfarin sodium therapy
87. Normal cortical bone mass in patients after long term Coumadin therapy
88. Vitamin K and maintenance of skeletal integrity in adults
89. Osteoporosis: A potential complication of long term warfarin therapy
90. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
91. Selective inhibition of thrombin by (2R,4R)-4methyl-1[N2- [(3-methyl-1,2, 3,4-tetrahydro-8-quinolinyl) sulfonyl]-1-arginyl)]-2-piperidinecarboxylic acid
92. Comparative effects of aspirin, a synthetic thrombin inhibitor, and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
93. Evidence for a rebound coagulation phenomenon after cessation of a 4 hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
94. Extended indications for placement of an inferior vena cava filter
95. Interruption of the vena cava by means of the Greenfield filter: Expanding the indications
96. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer
97. Thromboembolic complications in patients with advanced cancer: Anticoagulation versus Greenfield filter placement
98. Prophylactic vena cava filter insertion in severely injured trauma patients: Indications and preliminary results
99. Use of the Greenfield filter in patients with major trauma
100. Greenfield filter prophylaxis of pulmonary embolism in patients undergoing surgery for acetabular fracture
101. Pulmonary embolectomy by catheter device in massive pulmonary embolism
102. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis: The Prevention du Risque D'Embolie Pulmonaire par Interruption Cave Study Group
103. Technical aspects of insertion and removal of an inferior vena cava IVC filter for prophylactic treatment of pulmonary embolus
104. Pulmonary embolism in pediatric trauma patients
105. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood
106. Platelet hyporeactivity in very low birth weight neonates
107. Function and ultrastructure of platelets of neonates; Enhanced ristocetin aggregation of neonatal platelets
108. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma
109. Fetal and neonatal von Willebrand Factor (vWf) is unusually large and similar to the vWf in patients with thrombotic thrombocytopenic purpura
110. The bleeding time may be longer in children than in adults
111. Bleeding time in normal children
112. Late results after Starr-Edwards valve replacement in children
113. Prosthetic valves in children and adolescents
114. Five year follow-up after valve replacement with the St. Jude Medical valve in infants and children
115. Antiplatelet therapy in children with left-sided mechanical prostheses
116. The treatment of Kawasaki syndrome with intravenous gamma globulin
117. Ticlopidine: A new platelet aggregation inhibitor
118. Clopidogrel: An antithrombotic drug acting of the ADP-dependent activation pathway of human platelets
119. Clopidogrel, a novel antiplatelet and antithrombotic agent
120. Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers
121. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
122. Effect of ticlopidine on the long term patency of saphenous vein bypass grafts in the legs: Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie
123. Antiplatelet therapy following stent deployment
124. A randomised, blinded, trial of clopidogril versus aspirin in patients at risk of ischemic events (CAPRIE)
125. Platelet active drugs: The relationships among dose, effectiveness, and side effects
126. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy
127. Monitoring platelet GPIIb/IIIa antagonist therapy
128. Prophylactic indomethaein for prevention of intraventricular hemorrhage in premature infants
129. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants
130. Randomized low dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates
131. Intraventricular hemorrhage of the preterm neonate: Prevention studies
132. Partial plasma exchange transfusion improves cerebral hemodymamics in symptomatic neonatal polycythemia
133. Trends in the incidence of Reye's syndrome and the use of aspirin
134. Reye syndrome and juvenile rheumatoid arthritis in Michigan
135. Toxic encephalopathy with hyperammonaemia during high-dose salicylate therapy
136. Reye's syndrome and salicylate use
137. Reye's syndrome and medication use
138. Reye's syndrome associated with long-term aspirin therapy
139. Aspirin in the treatment of juvenile arthritis
140. Comparative study of the fibrinolytic system in human fetuses and in pregnant women
141. Newborn's fibrinolytic mechanism: Components and plasmin generation
142. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration
143. Anisoylated streptokinase-plasminogen activator complex offers no advantage over streptokinase for fibrin clot lysis in cord plasma
144. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric liver transplant patients
145. Thrombolytic therapy in pediatric patients: A comprehensive review of the literature
146. Monitoring thrombolytic therapy
147. Urokinase therapy in neonates with catheter related central venous thrombosis
148. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction, phase II, pilot and clinical trial
149. Local thrombolytic therapy in children
150. Urokinase thrombolysis using a multiple side hole multilumen infusion catheter
151. Intracerebral hemorrhage during fibrinolytic therapy in children: A review of the literature of the last thirty years
152. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
153. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
154. Reduction in fatal pulmonary embolism and venous thrombosis by perioperarive administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery
155. Prevention of venous thromboembolism in general surgical patients
156. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia
157. Spontaneous, lower-extremity venous thrombosis in children
158. Pulmonary embolism in adolescents
159. Neonatal symptomatic thromboembolism in Germany: Two year survey
160. Neonatal thrombosis: Report of a prospective Canadian and international registry
161. Venous thromboembolism and other venous disease in the Tecumseh Community Health Study
162. The incidence of venous thrombosis and its sequelae in certain districts in Sweden
163. The epidemiology of venous thrombosis
164. Thromboembolic complications following scoliosis surgery in Scandinavia
165. Venous thromboembolism complications in children: A critical review of the literature
166. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients
167. Alpha-2-macroglobulin remains as important as ATIII for thrombin regulation in cord plasma in the presence of endothelial cell surfaces
168. Anticoagulant dermatan sulfate proteoglycan (Decorin) in the term human placenta
169. An anticoagulant dermatan sulfate circulates in the pregnant woman and her fetus
170. Thrombin regulation in mother and fetus during pregnancy
171. Thrombin generation in newborn and adult plasma in the presence of an endothelial surface
172. Morphological and biochemical features affecting the antithrombotic properties of the inferior vena cava in adult rabbits and rabbit pups
173. Morphological and biochemical features affecting the antithrombotic properties of the aorta of adult rabbits and rabbit pups
174. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry
175. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus in children: A cross-sectional study
176. Thrombosis in systemic lupus erythematosus: A French collaborative study
177. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood; the Childhood Thrombophilia Study Group
178. Childhood thrombosis
179. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism
180. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism
181. Pulmonary embolism in younger adults
182. Postoperative chylothorax in children: Differences between vascular and traumatic origin
183. Fatal pulmonary embolism following removal of a central venous catheter
184. Complications of superior versus inferior vena cava occlusion in infants receiving central total parenteral nutrition
185. Complications of TPN catheter-induced vena caval thrombosis in children less than one year of age
186. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery
187. Right atrial thrombus and superior vena cava syndrome in a child
188. Iatrogenic superior vena cava syndrome: A new entity
189. Lethal chylothoraces due to superior vena caval thrombosis in infants
190. Recurrent bilateral pleural effusions secondary to superior vena cava obstruction as a complication of central venous catheterization
191. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home
192. Thrombosis and embolism in long-term central venous access for parenteral nutrition
193. Central venous catheter related thrombosis (CVL-related DVT) in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications
194. Right atrial thrombus formation screening using two-dimensional echocardiograms in neonates with central venous catheters
195. Multiple purpose central venous access in infants less than 1,000 grams
196. Incidence and risk factors of catheter related deep vein thrombosis in a pediatric intensive care unit: A prospective study
197. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial
198. Upper extremity deep venous thrombosis in cancer patients with venous access devices: Prophylaxis with a low molecular weight heparin (Fragmin)
199. Central venous catheters for out-patient management of malignant disorders
200. Inherited predisposition to thrombosis
201. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism
202. Thrombophilia as a multigenic disorder
203. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families
204. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S
205. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency
206. Incidence of venous thromboembolism in families with inherited thrombophilia
207. Ischemic stroke in infancy and childhood: Role of Arg506 to Gln mutation in the factor V gene
208. The factor V Leiden mutation in children with cancer and thrombosis
209. Antiphospholipid antibodies and coagulation regulatory protein abnormalities in children with pulmonary embolism
210. Thrombosis in otherwise well children with the factor V Leiden mutation
211. Prothrombotic disorders in infants and children with cerebral thromboembolism
212. Deep vein thrombosis in a 13 year old boy with hereditary protein S deficiency and a review of the pediatric literature
213. Severe cerebral venous sinus thrombosis and dural arteriovenous fistula in an infant with protein S deficiency
214. Protein S deficiency presenting as an acute postoperative arterial thrombosis in a four year old child
215. Moyamoya disease and protein S deficiency: A case report
216. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease
217. Childhood stroke associated with familial protein S deficiency
218. Arterial thrombosis and protein S deficiency
219. Superior sagittal sinus thrombosis in a child with protein S deficiency
220. Protein S deficiency: Early presentation and pulmonary hypertension
221. Bone mineral density and its association with inherited protein S deficiency
222. Severe deep vein thrombosis in a 2 year old child with protein S deficiency
223. The clinical outcome after inferior vena cava thrombosis in early infancy
224. Clinical manifestations in thrombotic children with factor V Leiden mutation
225. Prevalence of factor V Leiden in children with thromboembolism
226. Activated protein C resistance and the factor V Leiden mutation in children with thrombosis
227. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease
228. Inherited risk factors for thrombophilia in children with nephrotic syndrome
229. Factor V Leiden is not common in children with portal vein thrombosis
230. Prevalence of factor V Leiden in a population of patients with congenital heart disease
231. Factor V Leiden, prothrombin 20210G-A and the MTHFR C677T mutation in childhood stroke
232. Inheritied prothrombotic states and ischemic stroke in childhood
233. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke
234. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis
235. Cerebral venous sinus thrombosis in infancy and childhood: Role of genetic and acquired risk factors of thrombophilia
236. Prothrombin G20210A mutation in a child with spinal cord infarction
237. Severe thrombophilia in a pediatric patients with end-stage renal disease: Detection of the prothrombin gene G20210A mutation
238. Purpura fulminans: A cutaneous manifestation of severe protein C defidency
239. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis
240. Dermatopathology of skin necrosis associated with purpura fulminans
241. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis
242. Protein C survival during replacement therapy in homozygous protein C deficiency
243. Late-onset homozygous protein C deficiency manifesting cerebral infarction as the first symptom at age 27
244. Homozygous protein C deficiency identification of a novel missense mutation that causes impaired secretion of the mutant protein C
245. Evaluation of a new protein C concentrate and comparison of protein C assays in a child with congenital protein C deficiency
246. Late-onset homozygous protein C deficiency
247. Two-dimensional echocardiographic diagnosis of tricuspid valve noninfective endocarditis due to protein C deficiency (lesion mimicking tricuspid valve myxoma)
248. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies
249. Asymptomatic homozygous protein C deficiency
250. Homozygous protein C deficiency in two siblings
251. Hereditary, dysfunctional protein C molecules (type II): Assay characterization and proposed classification
252. Report on the diagnosis and treatment of homozygous protein C deficiency
253. The relative frequency of hereditary thrombotic disorders among 107 patients and thrombophilia in Israel
254. Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months
255. Homozygous protein C deficiency: Early treatment with Warfarin
256. Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S
257. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency
258. Successful treatment of homozygous protein C deficiency by hepatic transplantation
259. Severe protein C deficiency in newborn infants
260. Homozygous protein C deficiency: Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy
261. Absence of thrombosis in subjects with heterozygous protein C deficiency
262. Protein C deficiency
263. Diagnosis and treatment of homozygous protein C deficiency: Report of the Working Party on Homozygous Protein C and Protein S, International Committee on Thrombosis and Haemostasis
264. Homozygous protein C deficiency: Description of a new mutation and successful treatment with low molecular weight heparin
265. Ophthalmic manifestation of congenital protein C deficiency
266. Homozygous protein S deficiency in an infant with purpura fulminans
267. Homozygous protein C deficiency in a newborn: Clinicopathologic correlation
268. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant
269. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn
270. Severe homozygous protein C deficiency
271. Severe inherited "homozygous" protein C deficiency in a newborn infant
272. Neonatal purpura fulminans: A genetic disorder related to the absence of protein C in blood
273. Purpura fulminans in a Chinese boy with congenital protein C deficiency
274. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
275. Takayasu arteritis in Korean children: Clinical report of seventy cases
276. Takayasu arteritis in China: A report of 530 cases
277. Spontaneons recanalization of renal artery stenosis in childhood Takayasu arteritis: A case report
278. False-negative duplex Doppler studies in children with hepatic, artery thrombosis after liver transplantation
279. Duplex sonography of hepatic artery thrombosis after liver transplantation
280. The hepatic artery in orthotopic liver transplantation
281. Treatment of grafts and major vessel thrombosis with low-dose streptokinase in children
282. Renal artery thrombosis associated with elevated cyclosporine levels: A case report and review of the literature
283. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease
284. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease
285. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children
286. Attempts to reduce arterial thrombosis after cardiac catheterization in children: Use of percutaneous technique and aspirin
287. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin doses
288. MR diagnosis of dural venous sinus thrombosis complicating L-asparaginase therapy
289. Umbilical artery catheter blood sampling alters cerebral blood flow velocity in preterm infants
290. Umbilical artery catheter use: Report of an audit by study group for complications of perinatal care
291. Effect of umbilical artery catheterization in mesenteric hemodynamics
292. Effect of heparinization of fluids infused through an umbilical artery catheter on catheter patency and frequency of complications
293. Efficacy of thromboresistant umbilical artery catheters in reducing aortic thrombosis and related complications
294. Prevention of umbilical artery catheter clots with heparinized infusates
295. Continuous versus intermittent heparin infusion of umbilical artery catheters in the newborn infant
296. Effect of heparin infusates in umbilical arterial catheters on frequency of thrombotic complications
297. Effect of adding heparin in very low concentration to the infusate to prolong the patency of umbilical artery catheters
298. Heparin and the risk of intraventricular hemorrhage among very low birth weight infants
299. Heparin use a risk factor for intraventricular hemorrhage in low birth weight infants
300. The association of heparin exposure with intraventricular hemorrhage among very low birth weight infants
301. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment
302. Cardiac valve replacement in children: Comparison of tissue with mechanical prostheses
303. Late spontaneous disruption of a porcine xenograft mitral valve: Clinical, hemodynamic, echocardiographic, and pathologic findings
304. Late failure of porcine valve heterografts in children
305. Calcification in porcine xenograft valves in children
306. Porcine valve durability in children
307. Experience with aortic and mitral valve replacement in children
308. The durability of porcine xenograft valves and conduits in children
309. Calcification of porcine bioprostheses in children
310. Mechanical valve in aortic position is a valid option in children and adolescents
311. Performance of aortic and pulmonary liomografts in the right ventricular outflow tract in children
312. Comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement
313. Prospective trial of dipyridamole and warfarin in heart valve patients
314. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
315. Obstruction of mechanical valve prosthesis: Clinical diagnosis and surgical or nonsurgical treatment
316. Determination of markers of coagulation activation and reactive fibrinolysis in patients with mechanical heart valve prosthesis at different intensities of oral anticoagulation
317. Long-time observations on the Blalock-Taussig operation: IX. Single ventricle (with apex to the left)
318. Systemic-pulmonary arterial shunts in the first year of life
319. Modified Blalock-Taussig shunts: Results in infants less than 3 months of age
320. Modified Blalock-Taussig shunts: To heparinize or not to heparinize?
321. Thromboembolic complications after Fontan procedures: The role of prophylactic anticoagulation
322. Use of endovascular stents to increase pulmonary blood flow in pulmonary atresia with ventricular septal defect
323. Myocardial infarction in a neonate with hereditary antithrombin III deficiency
324. Heparin therapy during cardiopulmonary bypass requires ongoing quality control
325. Heparin need of the patients with cyanotic congenital heart disease during cardiopulmonary bypass
326. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass
327. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis
328. ECMO without heparin: Laboratory and clinical experience
329. Inactivation of heparin during extracorporeal circulation in infants
330. Aminocaproic acid decreases the incidence of intracranial hemorrhage and other hemorrhagic complications of ECMO
331. Anticoagulation for continuous arteriovenous hemofiltration in children
332. Continuous arteriovenous hemofiltration in children with postoperative cardiac failure
333. Early experience with continuous arteriovenous hemofiltration in critically ill pediatric patients
334. Atrophie blanche with onset in childhood
335. Preliminary report: Treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole
336. The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function
337. Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome
338. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: A prospective, randomized study
339. Homocystinemia: Vascular injury and arterial thrombosis
340. Platelet survival and morphology in homocystinuria due to cystathionone synthase deficiency
341. Pulmonary embolism in a homocystinuric patient dining treatment with dipyridamole and acetylsalicylic acid
342. Therapeutic levels of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: Review of literature and recommendations based on international normalized ratio
343. Late results after left-sided cardiac valve replacement in children
344. The St. Jude Medical cardiac valve and children: Role of anticoagulant therapy
345. Mitral valve replacement in children
346. Mechanical valve replacement in children and teenagers